PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24556618-2	2014	Early clinical trial data with rucaparib suggested that it caused sustained PARP inhibition.	rucaparib	31-40	poly (ADP-ribose) polymerase family, member 1	Mus musculus	76-80	
24556618-7	2014	Rucaparib is retained in cells and inhibits PARP >=50% for >=72 h days after a 30-min pulse of 400 nM.	rucaparib	0-9	poly (ADP-ribose) polymerase family, member 1	Mus musculus	44-48	
24556618-11	2014	CONCLUSIONS: Rucaparib accumulates and is retained in tumour cells and inhibits PARP for long periods such that weekly schedules have equivalent anticancer activity to daily dosing in a pre-clinical model, suggesting that clinical evaluation of alternative schedules of rucaparib should be considered.	rucaparib	13-22	poly (ADP-ribose) polymerase family, member 1	Mus musculus	80-84